|28th December 2020||Mark G Currie||20,107||Open or private sale||$3.01||$60,522.07|
|8th December 2020||Terrance Mcguire||51,457||Conversion of derivative||$0.00|
|8th December 2020||Terrance Mcguire||78,947||Open or private purchase||$19.00||$1,499,993.00|
|9th November 2020||Andreas Busch||125,000||Open or private purchase||$2.53||$316,250.00|
|23rd June 2020||Terrance Mcguire||4,377||Open or private sale||$31.54||$138,062.84|
|23rd June 2020||Marsha Fanucci||33,781||Open or private sale||$0.00|
|23rd June 2020||Marsha Fanucci||14,026||Open or private sale||$0.00|
|23rd June 2020||Marsha Fanucci||10,240||Open or private sale||$0.00|
|23rd June 2020||Marsha Fanucci||9,847||Open or private sale||$0.00|
|23rd June 2020||Marsha Fanucci||52,532||Open or private purchase||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Cyclerion Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments for serious and orphan diseases. Its product pipeline includes several sGC stimulators. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.